Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
BMS Japan “On Track” to Double Sales by 2032 as Launch Wave Nears
Quick Look: BMS Japan plans 50-plus approvals in 2027-2031 and over 10 new launches by 2030 as it aims to double sales by 2032 from 2023 levels. The expansion is set to offset upcoming patent losses for Opdivo and Eliquis,…
To read the full story
Related Article
BUSINESS
- Japan Approves Fuji’s New Stelara, Simponi Biosimilar Formulations
September 17, 2026
- Maruishi Clinches Japan Rights to Kringle’s Vocal Fold Scar Drug
September 17, 2026
- Nobelpharma, Fuso to Co-Promote Hypozincemia Drug Zintus
September 17, 2026
- Sanofi Japan Targets AI Fluency across Workforce by End-2027
September 16, 2026
- Mounjaro Label Updated with PIII CV Data Showing Noninferiority
September 16, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…